Huakang Biomedical Holdings Company Limited Provided earnings guidance for the nine months ended 30 September 2019. For the period, the group is expected to record a decrease in revenue for the nine months ended 30 September 2019 (the "2019 Third Quarterly Revenue") by approximately 12.5% as compared with that of the corresponding period of 2018. The Group is also expected to record a decrease in profit before listing expenses for the nine months ended 30 September 2019 by approximately 73.1% as compared with that of the corresponding period of 2018.